Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results

Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 3c, Revenues Beat

August 8, 2019 6:55 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $56.7 million versus the consensus estimate of $53.59 million.

Highlights include:

Adjusted EBITDA for the first quarter of Fiscal 2020 was $86.8 million, which includes an $11.2 million loss related to our Refined Products and Renewables segment for the period, compared to $80.3 million for the first quarter of... More